Adolescent Idiopathic Scoliosis International Spine Surgery Center

TOMORROW´S HEALTHCARE, TODAY

EpiDisease SL is an innovative Spanish biotechnology company that has positioned itself as a pioneer in the research and development of clinical tools based on genetic and epigenetic advances. With over 10 years of dedication and effort, EpiDisease SL is committed to offering solutions that bring the healthcare of the future to today. Its flagship product, ScoliGEN, is a clear example of its cutting-edge scientific work, providing a test that enables more precise and personalized management of children with AIS (Adolescent Idiopathic Scoliosis).

At EpiDisease, science and health come together to transform medical care and provide patients with the best opportunities for their well-being.

At EpiDisease SL, we are excited to announce our collaboration with the International Spine Surgery Center (CICCO) to offer cutting-edge in vitro diagnostic (IVD) tools: ScoliGEN and ScoliMIR. These innovative solutions, developed after 10 years of research and development, are specifically designed for patients with Adolescent Idiopathic Scoliosis (AIS) and their families. The availability of ScoliGEN and ScoliMIR at CICCO represents a global milestone in the integration of genetics and epigenetics in scoliosis management. These tools enable a precise and personalized approach, providing physicians with valuable information that can guide clinical decisions and improve outcomes and quality of life for children affected by this condition, and their families.

The CICCO Team

With over 30 years of experience, Dr. Rafael González Díaz is the director of the International Spine Surgery Center (CICCO), where he leads a team of distinguished spine specialists in Madrid. He has been recognized as one of the 10 most prestigious orthopedic and trauma surgeons in Spain, and in 2023 he was awarded as the best Spine Surgeon in the country. His career as a spine surgeon has earned him multiple awards and recognitions, establishing him as a national and international reference in advanced and complex spinal surgery.

Dr. Francisco Javier Ortega is a key member of the CICCO team, thanks to his extensive experience as a spine surgeon. His deep knowledge in various areas related to spinal pathology and his surgical skill make him an outstanding specialist, particularly in the treatment of complex conditions and vertebral fracture surgery.

Dr. Rosa Egea is recognized as one of the most outstanding spine surgeons in Spain, focusing her work exclusively on spinal pathologies. She specializes in pediatric and adolescent spine surgery, addressing cases of scoliosis and deformities. In addition, she combines her work at CICCO with her role at the Niño Jesús University Children’s Hospital in Madrid, a national reference center for the treatment of the most complex spine and scoliosis cases. Dr. Egea is one of the lead researchers involved in the pioneering development of EpiDisease’s genetic and epigenetic clinical tools.

What are ScoliGEN and ScoliMIR?

ScoliGEN: This genetic tool evaluates the genetic profile, identifying variants that may influence the progression of scoliosis. With this information, physicians can personalize treatment plans for each child and more effectively plan how they respond to the evolution of the disease.

ScoliGEN is currently available

ScoliMIR: This epigenetic tool provides information on how environmental and lifestyle factors can affect gene expression related to scoliosis. With this information, physicians can diagnose and predict the progression of the spine, and also monitor the effectiveness of their conservative interventions, adjusting, optimizing, and personalizing their approach for each case.

ScoliMIR is currently under regulatory review. It is expected to be commercially available for patients in the fourth quarter of 2024.

A Personalized Approach for Each Patient

The collaboration between EpiDisease SL and CICCO not only represents a breakthrough in medical technology, but also reflects our shared commitment to improving the quality of life for young people with AIS. By bringing the power of genetics and epigenetics closer to treatment, we are empowering physicians and families to make informed, data-driven decisions. We are excited about the future and the positive impact that ScoliGEN and ScoliMIR will have on the lives of patients and their families. Together, we are paving the way toward a more effective and personalized approach to managing adolescent idiopathic scoliosis. For more information on how these tools can benefit your family, please feel free to contact the physicians at CICCO.